Publications
Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site Vrije Universiteit Brussel
UNLABELLED: Nanobodies, or VHHs, that recognize poliovirus type 1 have previously been selected and characterized as candidates for antiviral agents or reagents for standardization of vaccine quality control. In this study, we present high-resolution cryo-electron microscopy reconstructions of poliovirus with five neutralizing VHHs. All VHHs bind the capsid in the canyon at sites that extensively overlap the poliovirus receptor-binding site. ...
Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus Institute of Tropical Medicine
BACKGROUND: We lack the rationale on which to base the development of a yellow fever (YF) vaccination schedule for people living with human immunodeficiency virus (PLWHIV).
OBJECTIVES: To report on the current evidence regarding the seroconversion rate and the duration of humoral protection after YF vaccine, as well as the impact of revaccination in PLWHIV.
DATA SOURCES: MEDLINE, Google Scholar, LILACS and Cochrane CENTRAL ...
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster Institute of Tropical Medicine
Reinfections with SARS-CoV-2 have already been documented in humans, although its real incidence is currently unknown. Besides having a great impact on public health, this phenomenon raises the question of immunity generated by a single infection is sufficient to provide sterilizing/protective immunity to a subsequent SARS-CoV-2 re-exposure. The Golden Syrian hamster is a manageable animal model to explore immunological mechanisms able to ...
Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research Vrije Universiteit Brussel University of Antwerp
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease ...
JCV serology in time Vrije Universiteit Brussel
OBJECTIVES: Although many neurologists are reluctant to use natalizumab in MS (multiple sclerosis) given the increased risk for PML (progressive multifocal leukoencephalopathy), trust was regained with the introduction of JCV antibody titres as a potent disease-modifying therapy. Literature shows that in patients with a negative JCV serology, the risk of PML is virtually non-existent. Unfortunately, seroconversion causes concern amongst many ...
Serologic and immunologic studies in patients with AIDS in North America and Africa; the potential role of infectious agents as cofactors in human immunodeficiency virus infection Institute of Tropical Medicine
Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein Institute of Tropical Medicine
Our knowledge of the binding sites for neutralizing Abs (NAb) that recognize a broad range of HIV-1 strains (bNAb) has substantially increased in recent years. However, gaps remain in our understanding of how to focus B cell responses to vulnerable conserved sites within the HIV-1 envelope glycoprotein (Env). In this article, we report an immunization strategy composed of a trivalent HIV-1 (clade B envs) DNA prime, followed by a SIVmac239 ...
Applications of nanobodies in brain diseases Vrije Universiteit Brussel Flanders Institute for Biotechnology
Nanobodies are antibody fragments derived from camelids, naturally endowed with properties like low molecular weight, high affinity and low immunogenicity, which contribute to their effective use as research tools, but also as diagnostic and therapeutic agents in a wide range of diseases, including brain diseases. Also, with the success of Caplacizumab, the first approved nanobody drug which was established as a first-in-class medication to ...